Influenza Diagnostics Market Size
The market for influenza diagnostics, estimated at US$8.5 billion in 2024, is expected to rise at a compound annual growth rate (CAGR) of 10.40% to US$21 billion by 2034.
The infection of respiratory organs such as the nose, throat, and lungs is known as influenza diagnostics. Another name for influenza is "Flu." Influenza A, B, C, and D viruses are among the four types of influenza viruses. Every winter, the human influenza A and B virus in the United States causes seasonal flu. Pandemics caused by influenza viruses are limited to influenza A. Heart inflammation, multiple organ failure, including renal and respiratory failure, muscle tissue inflammation, etc., are all brought on by influenza. There are numerous diagnostic tests available to test for influenza. Diagnostic procedures such as reverse transcriptase PCR (RT-PCR), rapid molecular assays, viral culture, and serology influenza virus diagnosis can be accomplished using a variety of diagnostic test types, including polymerase chain reaction and rapid antigen testing. The gold standard for influenza virus confirmation is now RT-PCR. Influenza can be identified through a blood test or by collecting a respiratory tract sample. Animals carry the influenza A virus, while humans contract the influenza B virus. The influenza A and influenza B strains are spread through respiratory droplets from coughing and by direct contact with an infected individual. The most prevalent influenza virus is called influenza A. When healthy people breathe in microscopic airborne droplets from an infected cough or sneeze, they contract the influenza virus.